Crossmark

Anti-OAcGD2 antibody in combination with ceramide kinase inhibitor mediates potent antitumor cytotoxicity against breast cancer and diffuse intrinsic pontine glioma cells

Crossref DOI link: https://doi.org/10.1007/s11010-024-05127-5

Published Online: 2024-10-12

Published Print: 2025-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kasprowicz, Angelina

Cavdarli, Sumeyye

Delannoy, Philippe

Le Guezennec, Xavier

Defebvre, Clémence

Spriet, Corentin

Jonckheere, Nicolas

Le Doussal, Jean-Marc

Krzewinski-Recchi, Marie-Ange

Mitra, Suman

Meignan, Samuel

Groux-Degroote, Sophie
Funding

Funding for this research was provided by:

Ligue Contre le Cancer
License Information

Text and Data Mining valid from 2024-10-12

Version of Record valid from 2024-10-12
More Information

Article History

Received: 10 April 2024

Accepted: 27 September 2024

First Online: 12 October 2024

Declarations

:

: The authors declare no competing interests.

: Not applicable.

: Not applicable.

: Not applicable.

Document is current

Any future updates will be listed below